PCK#

Related by string. * * therapeutic peptide PCK# *

Related by context. All words. (Click for frequent words.) 69 ATL# [001] 69 vascular disrupting agent 68 darinaparsin 67 YONDELIS 67 PEG SN# 67 Azedra 67 Aplidin 66 HDAC Inhibitor 66 depsipeptide 66 CBLC# 66 oral prodrug 66 CR# vcMMAE 66 DXL# 66 indibulin 66 Symadex 66 GLP toxicology studies 66 investigational humanized monoclonal antibody 66 Panzem 66 ganetespib 66 AEG# 66 Tyrima 66 Darinaparsin 66 ATL/TV# 66 atacicept 66 PXD# 66 XmAb# 65 GAP #B# 65 RGB # 65 HuMax CD4 65 ISTODAX 65 PRT# 65 immune modulatory 65 Cetrorelix 65 BAL# [002] 65 alvespimycin 65 MEK inhibitor 65 CCX# 65 targeting CD# 65 OXi# 65 proteasome inhibitor 65 CEQ# 65 #ME# 65 Valortim ® 65 Onconase 65 AKT inhibitor 65 Virulizin ® 65 Tarvacin 65 AP# [003] 65 HuMax EGFr 65 HCV protease 65 EndoTAG TM -1 65 liposomal formulation 65 Bortezomib 64 OncoVEX GM CSF 64 mertansine 64 HuLuc# 64 brivaracetam 64 novel peptide 64 MAXY G# 64 Bezielle 64 Archexin 64 NXL# 64 vidofludimus 64 TACI Ig 64 favorable pharmacokinetic profile 64 eniluracil 64 Bendavia 64 ENMD # 64 CYT# 64 rBChE 64 APOPTONE 64 Posiphen 64 milatuzumab 64 MGCD# [001] 64 HQK 64 Vidofludimus 64 mitogen activated ERK kinase 64 histone deacetylase inhibitor 64 angiogenesis inhibitor 64 pan HDAC inhibitor 64 Xanafide 64 Sym# 64 Pimavanserin 64 Zybrestat 64 tanespimycin 64 IMA# 64 Thiovir 64 CoFactor 64 ISIS # 64 antitumor 64 seliciclib 64 BNC# 64 HGS ETR1 64 anticancer compound 64 INCB# [001] 64 Triolex 64 Guanilib 63 riociguat 63 ON #.Na 63 CCR9 antagonist 63 preclinically 63 BAL# [001] 63 Restanza 63 Hsp# inhibitor 63 HGS ETR2 63 Perifosine 63 AEZS 63 triphendiol 63 Carfilzomib 63 chemopreventive agent 63 ganaxolone 63 vascular disrupting agents 63 orally bioavailable 63 enzastaurin 63 Golimumab 63 HSP# inhibitor 63 Phase Ib study 63 histone deacetylase HDAC inhibitor 63 Valortim R 63 PDE4 inhibitor 63 AVN# [001] 63 receptor inhibitor 63 MDV# 63 Debio 63 TG# [001] 63 Dasatinib 63 Kahalalide F 63 Traficet EN 63 R roscovitine 63 PRTX 63 anticancer agent 63 multi kinase inhibitor 63 PSMA ADC 63 #I TM# 63 selective inhibition 63 Squalamine 63 RDEA# 63 LibiGel ® 63 antitumoral 63 PSN# [002] 63 Phase Ib clinical 63 Preclinical studies 63 JAK1 63 rNAPc2 63 secretory phospholipase A2 sPLA2 63 YONDELIS R 63 NVA# 63 SPC# [001] 63 cilengitide 63 imetelstat 63 Panzem R 63 Alpharadin 63 menadione 63 fosbretabulin 63 potent anticancer 63 entinostat 62 CA4P 62 Aplidin R 62 cytostatic 62 Elesclomol 62 TRIOLEX 62 PLK1 SNALP 62 pegylated 62 JAK inhibitors 62 romidepsin 62 Dalbavancin 62 Pazopanib 62 PLX cells 62 BZL# 62 PS# [001] 62 alkylating agent 62 delafloxacin 62 R#/MEM # 62 OMP #M# 62 anti leukemic 62 Laquinimod 62 immune modulation 62 HCV protease inhibitor 62 preclinical efficacy 62 Mipomersen 62 proteasome inhibitors 62 DACH platinum 62 CYT# potent vascular disrupting 62 Gleevec resistant 62 ZYBRESTAT 62 Plicera 62 demonstrated antitumor activity 62 JAK inhibitor 62 CORT # 62 IL #E 62 ANAVEX #-# [003] 62 tramiprosate 62 TREANDA 62 INGN 62 humanized anti 62 Solulin 62 SCH # 62 antiangiogenic 62 Amrubicin 62 AQ4N 62 DCCR 62 Tezampanel 62 radezolid 62 hematological cancers 62 SNT MC# 62 torezolid phosphate 62 Menerba 62 GLYX 62 ZK EPO 62 CGEN # 62 FGFR 62 allosteric modulator 62 resolvins 62 LY# [003] 62 anti amnesic 62 Phase Ib II 62 Apoptone 62 IAP inhibitor 62 Glufosfamide 62 Seliciclib 62 Romidepsin 62 Pharmacokinetic PK 62 SparVax TM 62 PEGPH# 62 AAG geldanamycin analog 62 Zoraxel 62 Synavive 62 veltuzumab 62 elesclomol 62 ELACYT 62 Tarvacin TM 62 siRNA therapeutics 62 metaglidasen 62 Alzhemed TM 62 AZILECT ® 61 GRN#L 61 CYC# 61 mapatumumab 61 kinase inhibitor 61 Cloretazine 61 antibody MT# 61 BCX# 61 Cethromycin 61 Hsp# inhibition 61 immune modulating 61 Panzem R NCD 61 obatoclax 61 Onalta 61 ImmunoVEX HSV2 61 Homspera 61 EZN 61 Zalypsis 61 BIBW 61 forodesine 61 Phase 2a trial 61 Preclinical studies suggest 61 Protexia ® 61 SAR# [004] 61 selective modulator 61 EOquin TM 61 Virulizin R 61 alagebrium 61 TLR antagonists 61 IRX 2 61 huC# DM4 61 selective kinase inhibitor 61 glucagon receptor 61 antibody MAb 61 mGluR2 NAM 61 phase IIb clinical 61 anticancer activity 61 Degarelix 61 DNA intercalator 61 Protexia R 61 flavopiridol 61 tafamidis 61 nicotinic alpha 7 61 retapamulin 61 CCR9 61 ThGRF 61 Cloretazine ® 61 teriflunomide 61 ASONEP 61 MEK inhibitors 61 Elagolix 61 ProSavin 61 Aurora Kinase 61 oral JAK1 61 DDP# 61 methylnaltrexone 61 TOLAMBA 61 Orazol 61 Phase Ib 61 Voreloxin 61 Phase 2b Clinical Trial 61 LHRH antagonist 61 VA# [002] 61 vascular disrupting 61 Aurora kinase 61 oxidative stress inducer 61 evaluating tivozanib 61 Phase 1a clinical 61 Phase #b/#a 61 Angiolix 61 TRO# 61 pharmacokinetic PK 61 phosphate S1P 61 Marqibo TM 61 telomerase therapeutic 61 JAK Inhibitor 61 5 HT6 receptor 61 PI3K inhibitor 61 vivo efficacy 61 CIMZIA TM 61 novel histone deacetylase 61 phase IIb trial 61 orally administered inhibitor 61 MT#/MEDI-# 61 Androxal TM 61 Bicifadine 61 REP# 61 VAPRISOL 61 paclitaxel Taxol 61 Sapacitabine 61 Blinatumomab 61 PhG alpha 1 61 immunomodulatory 61 mGlu2 3 61 pharmacological chaperone 61 epigenetic therapies 61 Ambrisentan 61 DAVANAT ® 61 sitaxsentan 61 ALN TTR# 61 nucleoside analog 61 davunetide 61 PKC# 61 Lenocta 61 tolerability profile 61 LT NS# 61 OMP #R# 61 Iloperidone 61 #D#C# 61 midstage trials 61 solithromycin 61 pharmacodynamic properties 60 Genasense ® oblimersen 60 Ophena 60 TAFA# 60 vinca alkaloid 60 KB# [002] 60 OMAPRO 60 tyrosine kinase inhibitor 60 HCV protease inhibitors 60 SB# ONX 60 CYT# QbG# 60 PHX# 60 TLR7 60 Bendamustine 60 Varespladib 60 eprotirome 60 antifibrotic 60 Hedgehog antagonist 60 preclinical studies 60 Hsp# Inhibitor 60 KSP inhibitor 60 angiogenesis inhibition 60 Curaxin CBLC# 60 phase IIa clinical 60 thalidomide Thalomid 60 ospemifene 60 Curaxin 60 tezampanel 60 Atiprimod 60 Pertuzumab 60 PI3K Akt 60 elotuzumab 60 thymalfasin 60 IAP inhibitors 60 phase Ib 60 TLR9 agonist 60 Aflibercept 60 cMET 60 radiolabeled 60 CaPre TM 60 MORAb 60 Valortim 60 small molecule Hedgehog 60 antisense oligonucleotide 60 Epratuzumab 60 neuroprotective properties 60 receptor tyrosine kinase inhibitor 60 ORAL Sync 60 ONCONASE 60 sulodexide 60 AVE# 60 lucinactant 60 non nucleoside inhibitor 60 rxRNA 60 TLR9 agonists 60 BiTE 60 AZILECT R 60 JAK2 inhibitors 60 Vandetanib 60 bortezomib Velcade 60 Tanespimycin 60 neuroregenerative 60 radiotherapeutic 60 Amigal 60 Irinotecan 60 DOS# 60 EGS# 60 Pivotal Phase III 60 PI3 kinase inhibitors 60 virus HCV protease inhibitor 60 protein kinase inhibitor 60 axitinib 60 Reolysin 60 XYOTAX TM 60 registrational 60 Talabostat 60 alpha#beta# integrin 60 epothilone 60 Ceflatonin 60 gastrointestinal stromal tumors GIST 60 Protectan CBLB# 60 HspE7 60 Enhanze Technology 60 mTOR inhibitor 60 highly immunogenic 60 FOLOTYN ® 60 favorable pharmacokinetic 60 CD# antibody [001] 60 Phase #b/#a clinical 60 talabostat 60 Luteinizing Hormone Releasing Hormone 60 CRMD# 60 immunomodulating 60 potent inhibitor 60 NGX# 60 CG# [003] 60 cannabinor 60 Nanobody ® 60 AMPAKINE CX# 60 Phase III psoriasis 60 defensin mimetic antibiotic 60 Tamibarotene 60 highly selective inhibitor 60 Cloretazine R 60 kinase inhibition 60 otelixizumab 60 Denufosol 60 ENMD 60 BiTE antibody 60 CRx 60 pomalidomide 60 radiation sensitizer 60 sphingosine 1 60 Alocrest 60 Fulvestrant 60 SERMs 60 Ophena TM 60 therapeutic monoclonal antibody 60 Silodosin 60 Rasagiline 60 cediranib 60 adecatumumab 60 RhuDex 60 L BLP# 60 amrubicin 60 cabozantinib 60 administered subcutaneously 60 CRD5 60 Pafuramidine 60 Quinamed 60 lumiliximab 60 Radezolid 60 ixabepilone 60 Ozarelix 60 IND submission 60 Xinlay 60 antitumor activity 60 deforolimus 60 IL# PE#QQR 60 inhibits protein synthesis 60 immunotoxin 60 generation purine nucleoside 60 GMX# 60 Chemophase 60 erlotinib Tarceva 60 Asentar 60 seliciclib CYC# 60 XL# inhibits 60 HDAC inhibition 60 Trastuzumab 60 Phenoptin 60 KRN# 60 synthetic retinoid 60 luteinizing hormone releasing 60 Omacetaxine 60 GFT# 60 Vicriviroc 60 Cand5 60 TRAIL receptor antibodies 60 castrate resistant prostate cancer 60 HuMax CD# 60 targeted radiotherapeutic 60 Hsp# inhibitors 60 kallikrein 60 DAVANAT R 60 LEP ETU 60 Hedgehog signaling pathway 60 PD LID 60 Tesetaxel 60 Phase 2a 60 IFN alpha 60 ulimorelin 60 immunostimulatory 60 iSONEP 60 pharmacodynamic PD 59 Exherin TM 59 dose escalation clinical 59 voreloxin 59 ZD# [001] 59 nanoviricide 59 INCB# [002] 59 tesmilifene 59 squalamine 59 ARIKACE 59 elacytarabine 59 novel VDA molecule 59 humanized antibody 59 compound AEZS 59 antitumor effects 59 Aliskiren 59 RhuDex ® 59 drug conjugate 59 MLN# 59 Aclidinium 59 BLP# Liposome Vaccine 59 OvaRex ® MAb 59 Epothilones 59 miglustat 59 mGluR5 NAM 59 Pemetrexed 59 Targretin 59 CDK inhibitor 59 Capesaris 59 CBLB# 59 CXB# 59 Anavex #-# 59 Crizotinib 59 oral bioavailability 59 QLT# 59 AMD# [003] 59 mecamylamine 59 antisense inhibition 59 EOquin 59 S/GSK# 59 Aurora kinase inhibitor 59 ARRY # 59 CRLX# 59 ongoing Phase 1b 59 AACR NCI EORTC 59 Lacosamide 59 Homspera ® 59 BRIM2 59 CCR5 antagonist 59 EGFR HER2 59 hormone LHRH antagonist 59 Aganocide R 59 Anidulafungin 59 ADAGIO study 59 Presents Preclinical Data 59 TPI ASM8 59 viral kinetics 59 LymphoStat B 59 PROSTVAC TM 59 alefacept 59 incyclinide 59 belinostat 59 Serdaxin 59 HDACi 59 BRIM3 59 Phase 1b clinical trials 59 Huntexil 59 Removab 59 prodrug 59 Tasimelteon 59 GLPG# 59 GSK # 59 Phase IIB 59 BAY #-# 59 tolerability profiles 59 non nucleoside HCV 59 selective agonist 59 MGd 59 Onalta ™ 59 Omacetaxine mepesuccinate 59 interferon gamma 1b 59 non nucleoside 59 DFMO 59 oral antiviral 59 Genasense R oblimersen 59 cytoprotective 59 Phase 2a Clinical Trial 59 TRX1 59 humanized monoclonal 59 Zerenex 59 PI3K delta 59 anti angiogenic agent 59 Marqibo 59 ocular formulation 59 BN# [002] 59 Pharmacokinetics PK 59 Aviptadil 59 Kinase Inhibitor 59 oral FTY# 59 VitiGam 59 targeted antifolate 59 tezampanel NGX# 59 fipamezole 59 small molecule tyrosine 59 PNP inhibitor 59 Everolimus 59 microtubule inhibitor 59 SinuNase ™ 59 Apaziquone 59 partial agonist 59 NEUMUNE 59 PEGylated interferon 59 Pirfenidone 59 GW# [003] 59 polymerase inhibitors 59 TriRima 59 BRAF inhibitor 59 MEK inhibitor RDEA# 59 multikinase inhibitor 59 isoform selective 59 antitumor efficacy 59 cancer immunotherapies 59 Clinical Trial Results 59 perifosine 59 neurotrophic 59 goserelin 59 pralatrexate 59 GAMMAGARD 59 DiLA2 liposomes 59 Tarceva TM 59 selective antagonist 59 DiLA2 59 masitinib 59 Æterna Zentaris 59 lapatinib Tykerb 59 ataluren 59 Afatinib 59 Factor VIIa 59 Valdoxan 59 JAK2 59 rFIXFc 59 orally dosed 59 Safinamide 59 volociximab 59 Troxatyl 59 Caprospinol 59 neratinib 59 RNAi therapeutic targeting PCSK9 59 plasma pharmacokinetics 59 nucleoside analogues 59 Anti Tumor 59 ANG# 59 TELINTRA 59 HCD# [002] 59 reslizumab 59 picoplatin 59 preclinical 59 Zysolin TM 59 BioVant 59 CLL8 59 Mitoxantrone 59 Davanat 59 Cimzia ® certolizumab pegol 59 ceftazidime 59 Temsirolimus 59 Abiraterone acetate 59 Zolinza 59 XL# XL# 59 Icatibant 59 gastrin 59 pediatric acute lymphoblastic 59 aclidinium 59 docetaxel Taxotere R 59 small molecule defensin 59 Antiviral Activity 59 oral Xeloda 59 BiTE antibody MT# 59 potently inhibit 59 intranasal formulation 59 arbaclofen 59 IMC A# 59 SIRT1 activators 59 rilonacept 59 adipiplon 59 phase IIa 59 immunomodulator 59 Exelixis XL# 59 chemotherapeutic drug 59 SRT# [003] 59 ADVANCE PD 59 phase 2a 59 mda 7 59 VEGF receptor 59 CCR2 59 tkRNAi 59 celgosivir 59 enzyme inhibitor 59 immunomodulation 59 canakinumab 59 ESBA# 59 Nasulin 59 CINOD 59 TLK# 59 ofatumumab 59 tipifarnib 59 polymerase inhibitor 59 CIMZIA ™ 59 antithrombotic 59 Vilazodone 59 pentostatin 59 Annamycin 59 Antiangiogenic 59 oral salmon calcitonin 59 imatinib Gleevec ® 59 PF # [001] 59 CTAP# Capsules 59 novel prodrug 59 LY# [002] 59 OHR/AVR# 59 Phase #b/#a trial 59 teduglutide 59 HDL Selective Delipidation 58 ATL# [002] 58 RezularTM 58 phase IIb study 58 Presents Preclinical 58 NS#/#A protease 58 refractory acute myeloid 58 ARRY 58 tumor vascular disrupting 58 Sphingomab 58 decitabine 58 Prostate AdenoCarcinoma Treatment 58 signal transduction inhibitor 58 Eribulin 58 Arikace 58 omega interferon 58 Pralatrexate 58 Interferon alpha 58 NP2 Enkephalin 58 sipuleucel T 58 ularitide 58 compound PMX # 58 mTOR inhibition 58 antiangiogenic activity 58 AEOL # 58 Homspera TM 58 Muraglitazar 58 Dapagliflozin 58 Personalized Immunotherapy 58 CDP# 58 prostone 58 Phase Ia 58 Talactoferrin 58 OvaRex R 58 VEGFb 58 IMGN# 58 baminercept 58 IgG1 monoclonal antibody 58 MAb 58 Gleevec imatinib mesylate 58 polysaccharide polymer 58 triterpenoids 58 NexACT 58 PROVENGE sipuleucel T 58 midstage clinical 58 novel peptides 58 vosaroxin 58 sodium glucose cotransporter 58 atrasentan 58 small molecule inhibitors 58 acetonide FA 58 Urocidin 58 Liposomal 58 ZEVALIN ® 58 HGS# 58 PTP 1B 58 mediated inhibition 58 chimeric monoclonal antibody 58 geldanamycin 58 vitro studies 58 Vidaza azacitidine 58 tranilast 58 Trofex TM 58 ibudilast 58 Relivar 58 Eniluracil 58 Phase Ib clinical trials 58 Anthim 58 IFN Beta 58 ONCONASE R 58 beta 1a 58 velafermin 58 active moiety 58 uric acid lowering 58 daptomycin 58 trabectedin 58 anti CD3 antibody 58 Aurexis 58 oncolytic virus 58 anti proliferative 58 Randomized Phase 58 epothilones 58 tiapamil 58 maturation inhibitor 58 DAVANAT 58 deacetylase inhibitors 58 Allovectin 7 R 58 Enzyme Replacement Therapy 58 sapacitabine 58 FK# 58 Pyridorin 58 RLY# 58 selective androgen receptor modulator 58 ACAPODENE 58 bendamustine 58 estramustine 58 Tesmilifene 58 ZYBRESTAT TM 58 PEP# [003] 58 protein tyrosine phosphatase 1B 58 ponatinib 58 Actimmune ® 58 Antisense 58 Aganocide ® 58 GRNVAC1 58 induces apoptosis 58 Recombinant Human 58 biodistribution 58 CD# monoclonal antibody 58 E1 INT TM 58 vorinostat 58 Anticalin ® 58 danoprevir 58 antisense inhibitor 58 potent antiviral 58 Azedra TM 58 Trofex 58 IMiDs R 58 optimized siRNA 58 BEXXAR 58 Liprostin 58 oral rivaroxaban 58 bone metastasis 58 Tumour Vascular Disrupting Agent 58 telaprevir VX 58 IGF IR 58 investigational monoclonal antibody 58 oncolytic viruses 58 Solorel TM 58 TOCOSOL Paclitaxel 58 PDE# 58 BioNumerik 58 insulin sensitizing 58 posaconazole 58 resolvin 58 Cethrin R 58 antiangiogenic agent 58 bardoxolone 58 combinability 58 FLT3 58 Clevudine 58 Maribavir 58 alpha7 58 Dacogen injection 58 entity NCE 58 drug ISA# 58 VALSTAR 58 Ocrelizumab 58 NEUGENE 58 Pathway Inhibitor 58 olaparib 58 renin inhibitor 58 convenient dosing regimens 58 molecularly targeted 58 antitumour 58 miconazole Lauriad ® 58 LymphoStat B TM 58 vitro experiments 58 Enzastaurin 58 zileuton 58 Neuradiab 58 myeloproliferative diseases 58 Boceprevir 58 AMN# [001] 58 ZFP Therapeutic 58 EVIZON 58 tocilizumab 58 Insegia 58 docetaxel Taxotere ® 58 telomerase inhibitor 58 Maxy G# 58 sunitinib malate 58 Targeted Chemotherapy 58 Investigational Compound 58 immuno modulatory 58 R#/MEM 58 APTIVUS 58 Immunotherapeutic 58 nonclinical studies 58 Velcade bortezomib 58 5 HT3 antagonist 58 Clavis Pharma 58 intravenous dosing 58 prodrugs 58 trodusquemine 58 registrational trial 58 histone deacetylase HDAC 58 AeroLEF TM 58 TLR agonists 58 Zoledronic acid 58 oritavancin 58 p# inhibitor 58 peptide antigens 58 CD# CEA 58 Kevetrin ™ 58 palonosetron 58 nucleoside analogue 58 eltrombopag 58 cetuximab Erbitux 58 Triapine 58 Systemic Delivery 58 anti angiogenic agents 58 NS5A 58 Revlimid lenalidomide 58 VEGF Trap 58 Phase 2b 58 trastuzumab Herceptin 58 Preclinical Data 58 MKC# MKC# PP 58 ALN TTR 58 Aurora kinase inhibitors 58 Kamada AAT 58 RiVax 58 Methylnaltrexone 58 Trandolapril 58 cutaneous T cell 58 dasatinib Sprycel ® 58 antiapoptotic 58 anti angiogenic 58 velafermin belinostat 58 polycythemia vera PV 58 microtubule targeting 58 MET amplification 58 AMPA kainate 58 ALN PCS 58 TBC# 58 sulindac 58 HGS ETR1 mapatumumab 58 potentiator 58 histamine dihydrochloride 58 ELND# 58 ALN RSV# 58 Decitabine 58 Linaclotide 58 JAK2 inhibitor 58 anti CD3 58 preclinical pharmacokinetic 58 davunetide intranasal AL 58 biologic therapy 58 Abiraterone 58 NOX E# 58 #th Annual Interscience 58 superficial bladder cancer 58 phosphatidylserine PS targeting 58 renoprotective 58 octreotide acetate 58 hGH CTP 58 Spiegelmer ® 58 nucleoside 58 Locteron ® 58 hematological tumors 58 HER2 positive metastatic breast 58 Solazed TM 58 adecatumumab MT# 58 effector function 58 PRX# 58 glucokinase activator 58 Stedivaze 58 Nexavar sorafenib

Back to home page